Hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Molecular Medicine

Background:

• Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiomyopathy, a significant cause of illness and death.
• It is a sarcomeric disease resulting from genetic defects in sarcomere proteins, leading to left ventricular hypertrophy, hypercontractility, and diastolic dysfunction.
• HCM presents a heterogeneous spectrum of phenotypes, from mild, stable forms to severe childhood-onset cases causing heart failure and arrhythmias.

Purpose of the Study:

• To provide an overview of hypertrophic cardiomyopathy, encompassing its genetic basis, clinical presentation, diagnostic methods, and evolving therapeutic landscape.
• To highlight recent advancements in targeted therapies and future directions for managing HCM.

Main Methods:

• Review of current literature on hypertrophic cardiomyopathy genetics, pathophysiology, diagnosis, and treatment.
• Analysis of the efficacy and safety of novel therapeutic agents, including myosin inhibitors.
• Discussion of emerging treatment modalities, such as gene therapy.

Main Results:

• Multi-imaging techniques like echocardiography and cardiac MRI are crucial for HCM diagnosis and prognosis.
• Myosin inhibitors have demonstrated safety and efficacy in improving functional capacity and alleviating symptoms in HCM patients.
• Gene therapies targeting underlying genetic variants are under investigation as innovative treatment approaches.

Conclusions:

• HCM is a complex genetic disorder with a wide clinical variability.
• Recent therapeutic developments, particularly myosin inhibitors, offer significant improvements for patients.
• Future research in gene therapy holds promise for addressing the root cause of HCM.